Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | -2.84% | |
Volume Surge | Other | -2.84% | |
NR7 | Range Contraction | -2.84% | |
Inside Day | Range Contraction | -2.84% | |
Spinning Top | Other | -0.65% | |
Upper Bollinger Band Walk | Strength | -0.65% | |
Upper Bollinger Band Touch | Strength | -0.65% | |
180 Bullish Setup | Bullish Swing Setup | -1.93% | |
Upper Bollinger Band Walk | Strength | -1.93% | |
Above Upper BB | Strength | -1.93% |
Alert | Time |
---|---|
Down 2 % | about 9 hours ago |
Down 1% | about 9 hours ago |
Up 1% | about 9 hours ago |
Possible NR7 | 3 days ago |
Possible Inside Day | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/22/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Cancer Center Her2/Neu
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 7.58 |
Average Volume | 48,038 |
200-Day Moving Average | 12.13 |
50-Day Moving Average | 14.25 |
20-Day Moving Average | 15.44 |
10-Day Moving Average | 16.39 |
Average True Range | 1.40 |
RSI (14) | 58.16 |
ADX | 38.63 |
+DI | 25.13 |
-DI | 8.84 |
Chandelier Exit (Long, 3 ATRs) | 14.54 |
Chandelier Exit (Short, 3 ATRs) | 17.13 |
Upper Bollinger Bands | 17.67 |
Lower Bollinger Band | 13.21 |
Percent B (%b) | 0.8 |
BandWidth | 28.88 |
MACD Line | 0.72 |
MACD Signal Line | 0.56 |
MACD Histogram | 0.1646 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.98 | ||||
Resistance 3 (R3) | 18.97 | 18.24 | 18.61 | ||
Resistance 2 (R2) | 18.24 | 17.68 | 18.24 | 18.48 | |
Resistance 1 (R1) | 17.50 | 17.33 | 17.14 | 17.51 | 18.36 |
Pivot Point | 16.77 | 16.77 | 16.58 | 16.77 | 16.77 |
Support 1 (S1) | 16.03 | 16.21 | 15.67 | 16.04 | 15.18 |
Support 2 (S2) | 15.30 | 15.86 | 15.30 | 15.06 | |
Support 3 (S3) | 14.56 | 15.30 | 14.93 | ||
Support 4 (S4) | 14.57 |